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The adult heart responds to sustained pressure overload by devel-
oping ventricular hypertrophy. The signaling events mediating 
this process are substantially driven by activation of GPCRs, which 
in turn stimulate multiple downstream intracellular cascades. 
Exposure to sufficient magnitude and duration of GPCR stimula-
tion is thought to be necessary to tip the balance between adaptive 
and maladaptive responses (1, 2). However, the response may also 
depend upon how well the heart can mount countermeasures to 
effectively blunt such adverse signaling.
One set of negative controllers of GPCRs is the family of more 
than 30 regulator of G protein signaling (RGS) proteins (3). 
Upon GPCR activation, GDP is exchanged for GTP on the Gα 
subunit, allowing for dissociation from Gβγ subunits and activa-
tion of downstream effectors. RGS proteins inhibit these cas-
cades by accelerating Gα-dependent GTP hydrolysis to reconsti-
tute the heterotrimeric G protein complex. RGS proteins also 
act as effecter antagonists by physically blocking the binding of 
G protein subunits to their protein targets and interfering with 
downstream signaling proteins (4). RGS2–RGS5 are thought 
to be important in the heart (5, 6), although their precise roles 
remain unclear. Human heart failure is associated with increased 
RGS4 expression, whereas expression of RGS2 is unchanged (7). 
Forced overexpression of RGS4 blunts Gq-stimulated cardiac 
hypertrophy in rat neonatal cardiac myocytes (8) and intact 
hearts (9) and suppresses cardiac hypertrophy of transgenic 
mice lacking guanylate cyclase–A (natriuretic peptide-stimu-
lated cyclase; ref. 10). Yet other studies in hearts overexpress-
ing RGS4 found rapid cardiac dilation and marked mortality 
upon pressure overload induction (11), highlighting a complex 
role. This was further demonstrated by the recent discovery that 
RGS4 regulates parasympathetic (Gα[i/o]) signaling to control 
heart rate in the sinoatrial node (12).
In contrast to RGS4, which inactivates multiple Gα proteins 
(13), myocyte RGS2 appears more selective for Gαq (6, 14). Given 
the recognized and prominent role of Gq signaling to maladaptive 
remodeling as a result of pressure overload (15, 16), RGS2 is an 
intriguing candidate as an intrinsic suppressor of this pathobiol-
ogy. Mice globally lacking RGS2 were found to develop modest 
systemic hypertension, although they exhibit no major cardiac 
phenotype (17), which suggested that RGS2 had a modest role in 
the heart. Yet more recent studies found that knockdown of the 
gene encoding RGS2 amplifies hypertrophic responses in neonatal 
myocytes exposed to Gq stimuli (18).
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An important feature of both RGS2 and RGS4 is that they are 
activated by PKG, attenuating Gq-coupled vasoconstriction in 
vascular (19) and gastric (20) smooth muscle, and, in the case of 
RGS4, enhancing antihypertrophic effects of natriuretic peptides 
(10). Even more pronounced suppression of cardiac hypertrophy 
coupled to PKG activation has been achieved by inhibiting phos-
phodiesterase 5 (PDE5; ref. 21) with drugs widely used to treat 
erectile dysfunction (e.g., sildenafil). Given its greater selectivity 
for Gq, we hypothesized that RGS2 plays a particularly central role 
in the antihypertrophic effects of this therapy. Understanding 
such mechanisms has taken on clinical relevance, given the recent-
ly initiated NIH multicenter trial of the PDE5 inhibitor sildenafil 
for treating heart failure with a normal ejection fraction (RELAX 
study; http://clinicaltrials.gov/ct2/show/NCT00763867).
In the present study, we tested the role of RGS2 in pressure 
overload remodeling and its amelioration by PDE5 inhibition. 
Mice genetically lacking RGS2 did not compensate against pres-
sure overload, but instead developed rapid and marked cardiac 
hypertrophy and dysfunction and early lethality. In contrast, their 
response to swimming exercise was normal. In addition to target-
ing myocardial Gq signaling, RGS2 was found to be essential in 
order for PDE5 inhibition to reduce hypertrophy and improve car-
diac function upon exposure to pressure overload.
Results
RGS2 is expressed in adult mouse myocytes and suppresses Gq stimulation. 
RGS2 protein expression was detected in isolated adult myocytes 
from control Rgs2+/+, but not Rgs2–/–, mouse hearts (Figure 1A). 
RGS2-mediated protection against myocyte hypertrophy has been 
previously reported in neonatal myocytes using RGS2 RNAi (18). 
Here, we examined adult myocytes from Rgs2+/+ and Rgs2–/– mouse 
hearts and found enhanced protein synthesis in cells incubated 
with the Gq agonist endothelin-1 (ET1). This finding supports the 
role of RGS2 in countering such stimulation in adult cells.
Rgs2–/– mouse hearts develop marked hypertrophy and failure and early 
lethality from pressure overload. To test whether RGS2 is cardiopro-
tective against development of hypertrophy in vivo, Rgs2–/– mice 
(4–5 months old) were subjected to pressure overload by trans-
verse aortic constriction (TAC; ref. 21). Resting cardiac anatomy 
and global function, as assessed by echocardiography, was similar 
between Rgs2–/– and littermate control Rgs2+/+ mice (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI35620DS1). After TAC, however, Rgs2–/– mice devel-
oped marked hypertrophy (Figure 1C) and had a high mortality rate 
within 1 wk, whereas all Rgs2+/+ mice survived this period (Figure 
1D). Marked lung congestion (wet lung weight) was documented 
in surviving and deceased Rgs2–/– animals (Figure 1E), which sup-
ported heart failure as the cause of death. The increased heart mass 
was caused by both exacerbated myocyte hypertrophy and fibrosis 
(Figure 1F). Cardiac apoptosis was not observed within this 1-wk 
time period in either genotype (data not shown). TAC-induced 
changes in cardiac fetal genes Nppa, Nppb, and Myh7 were greater in 
Rgs2–/– than in Rgs2+/+ hearts, whereas expression of Atp2a2 declined 
in both models similarly (Supplemental Figure 1).
Chamber dilation and lack of functional compensation in Rgs2–/– TAC 
mouse hearts. Rgs2–/– hearts dilated after pressure overload, with 
end-diastolic and end-systolic dimensions increasing and frac-
tional shortening (FS) declining more than in Rgs2+/+ hearts (Fig-
ure 2A). These echocardiographic data were supported by more 
detailed invasive pressure-volume (PV) analysis (Figure 2, B–D). At 
rest, Rgs2–/– mice had LV peak systolic pressure that was increased 
about 15 mmHg compared with Rgs2+/+ mice and increased total 
LV afterload, as measured by effective arterial elastance (Figure 2C). 
However, basal cardiac systolic and diastolic function was essen-
tially identical between the groups (Supplemental Table 2). TAC 
increased cardiac afterload to near-identical levels in both geno-
types (Figure 2C), because load largely depended on the proximal 
aortic constriction. Similarities of loading changes after 48 h TAC 
were also confirmed (Supplemental Figure 2). In Rgs2+/+ mice, 1 wk 
TAC triggered functional compensation with enhanced contrac-
tility: the end-systolic PV relation shifted leftward with increased 
slope (Figure 2B). This did not occur in Rgs2–/– mice; instead, hearts 
dilated with a rightward shift of PV relations (Figure 2B). Summary 
data for contractility (end-systolic PV relation slope, volume posi-
tion, peak rate of LV pressure rise, and preload recruitable stroke 
work) and relaxation (peak rate of LV pressure decline and time 
constant tau) are provided in Figure 2D. Unlike control hearts, 
Rgs2–/– hearts failed to compensate by increasing contractility and 
had impaired relaxation, with net cardiac output depending more 
on marked chamber dilation (Frank-Starling law).
Early and robust activation of Gq-related pathways in Rgs2–/– TAC 
mouse hearts. Because RGS2 principally suppresses Gq signaling, 
we examined the activation of the phosphatase calcineurin (Cn), 
Ca2+-calmodulin–dependent kinase II (CaMKII), and the MAPKs 
ERK1/2, JNK, and p38, all of which are potentially activated by 
Gq-coupled stimuli and are associated with hypertrophy and/or 
cardiac dilation (2, 22). After 1 wk TAC, Cn protein expres-
sion rose modestly in Rgs2+/+ hearts, but markedly increased in 
Rgs2–/– hearts (Figure 3A). Parallel changes were observed in the 
gene expression of regulator of Cn-1 (RCAN-1), an index of Cn 
activity (Figure 3B). This was observed even after 48 h TAC in 
Rgs2–/– hearts, a time at which expression was otherwise unal-
tered. CaMKII activation also markedly increased after 48 h TAC 
in Rgs2–/– hearts and persisted at 1 wk TAC, whereas TAC Rgs2+/+ 
hearts showed minimal CaMKII activation (Figure 3C). Among 
the 3 MAPKs, we observed greater activation of ERK1/2 and JNK 
at both time points in Rgs2–/– hearts (Figure 3D). Phosphorylation 
of p38 rose markedly and similarly in both groups after 48 h TAC, 
but declined at 1 wk TAC, which suggests that it was regulated 
by alternative cascades. These early signaling responses were not 
coupled to changes in RGS2 expression in control myocardium or 
myocytes (data not shown).
Gq is a critical target of RGS2. To test whether Gq is indeed the critical 
target of RGS2 in the heart, we performed several studies whereby 
Gq signaling was modified. Activation of phospholipase Cβ (PLCβ) 
is a primary mechanism for Gαq signaling and is required for dilat-
ed cardiomyopathy to develop in cardiac-targeted Gαq-overexpress-
ing transgenic animals (referred to herein as Gαq-OE+; ref. 23). We 
therefore subjected Rgs2–/– hearts to 48 h TAC with or without 
cotreatment by a PLCβ inhibitor (U73122, 2.5mg/kg/d) or inactive 
control (U73343). Exacerbated LV hypertrophy, chamber dilation, 
and dysfunction were observed after 48 h TAC in Rgs2–/– mice, and 
all were prevented in animals receiving the PLCβ inhibitor, whereas 
the inactive analog at the same dose had no impact (Figure 4, A and 
B; see Supplemental Figure 2B for summary echo data).
In a second series of experiments, Gαq-OE+ mice (24) were bred with 
Rgs2–/– animals, and cardiac function and morphology were exam-
ined at 3–4 wk of age. Gαq-OE+Rgs2+/+ mice exhibited minimal hyper-
trophy, but slight chamber dilation and reduced FS. However, these 3 
were substantially worsened in Gαq-OE+Rgs2–/– mice (Figure 4, C–E). 
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Figure 1
Cardiac phenotype of Rgs2–/– mice. (A) Myocyte RGS2 protein expression was detected in Rgs2+/+ (+/+) cells, but not Rgs2–/– (–/–) cells. (B) 
Adult mouse myocytes (n = 5 per group) from Rgs2–/– hearts displayed an amplified growth response to ET1, as assessed by radiolabeled leu-
cine incorporation. P value shown is for interaction of genotype and condition (2-way ANOVA). #P < 0.01; ##P < 0.001. (C) Representative whole 
hearts, H&E-stained cross sections, and summary results for heart weight normalized to tibia length (HW/TL) in Rgs2+/+ and Rgs2–/– hearts 
subjected to 1 wk TAC. White bar shows data from deceased mice. (D) Kaplan-Meier survival curve showing markedly increased mortality in 
Rgs2–/– mice subjected to TAC compared with littermate controls. (E) Wet lung weight normalized to body weight (n = 8–13 per group). White bar 
shows data from deceased mice. (F) Representative Masson’s trichrome staining of the heart section. Blue stain indicates collagen deposition. 
Scale bars: 100 μm. Also shown are summary quantification results on myocyte diameter and collagen fraction (n = 4 hearts per group; >50 cells 
per heart; 5–6 sections for fibrosis analysis). *P < 0.05 versus Rgs2+/+ sham; §P < 0.05 versus Rgs2–/– sham; †P < 0.05 versus Rgs2+/+ TAC.
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Overexpression of Gαq itself lowered heart rate, as described previ-
ously (24), but this was not altered by deleting Rgs2.
Finally, we examined the cardiac response to a stress that did 
not involve Gq stimulation. Rgs2–/– and Rgs2+/+ mice were sub-
jected to 6 wk of swimming exercise (twice daily for 90 min). 
This regimen stimulated an increase in LV mass of about 30% 
in both groups, with no impairment of cardiac function (Figure 
4F). Protein analysis confirmed that Cn, CaMKII, and ERK1/2 
were not activated in either genotype by the exertional stress 
(Supplemental Figure 3). Thus, unlike our findings with TAC or 
Figure 2
Rgs2–/– hearts display chamber dilation and fail to compensate to TAC. (A) Echocardiographic data before and after 1 wk TAC (n = 7 per group). 
LV-Dd, LV end-diastolic dimension; LV-Ds, LV end-systolic dimension. #P < 0.05 versus Rgs2+/+ 1 wk TAC. (B) Representative PV loops during 
preload reduction by inferior vena cava occlusion in sham (thick line) and 1 wk TAC animals (thin dotted line). Steepness of left upper relation 
(end-systolic elastance [Ees]) reflected contractile function and was enhanced after TAC in Rgs2+/+ mice, but unaltered with a right-shift (remod-
eling) of the relation in Rgs2–/– mice. (C) Peak systolic LV pressure (LVP sys) and effective arterial elastance (Ea; an index of total ventricular 
afterload). Rgs2–/– mice had somewhat higher basal afterload, but both genotypes had similarly increased afterload after 1 wk TAC (n = 5–7 per 
group). P value shown is for interaction of genotype and condition. *P < 0.05 versus sham; †P < 0.05 versus Rgs2+/+ sham. (D) Summary data 
obtained from PV loop analysis shown in bar graphs. P values shown are for interaction of genotype and condition (2-way ANOVA). *P ≤ 0.001, 
†P < 0.05 versus sham. V100, volume position (end-systolic volume at common end-systolic pressure — 100 mmHg — derived from end-systolic 
PV relation); dP/dtmax, peak rate of LV pressure rise; PRSW, preload recruitable stroke work; dP/dtmin, peak rate of LV pressure decline; Tau, 
relaxation time constant; SV, stroke volume; CO, cardiac output. P values shown are for interaction of genotype and condition (2-way ANOVA). 
*P < 0.05, §P = 0.06 versus sham; †P < 0.05 versus corresponding Rgs2+/+ TAC and Rgs2–/– sham (1-way ANOVA).
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Gαq-OE+ animals, hypertrophic response that did not involve Gq 
signaling stimulation was not exacerbated by a lack of RGS2.
Antihypertrophic effect of PDE5 inhibition is absent in Rgs2–/– mouse 
hearts. In noncardiac cells, RGS2 is activated by PKG-1α binding and 
phosphorylation, inducing their translocation to the outer plasma 
membrane to inactivate Gq (19). In hearts exposed to stress, cardiac 
PKG can be potently activated by inhibiting the cGMP hydrolytic 
enzyme PDE5, which in turn suppresses hypertrophy and/or dys-
function in mice subjected to pressure overload (21). While various 
individual PKG targets may underlie this response (25), RGS2 could 
reflect a very proximal effecter that subsequently regulates multi-
ple downstream cascades. To test the importance of RGS2 to this 
regulation, mice were fed with the PDE5 inhibitor sildenafil dur-
ing 1 wk TAC. Sildenafil blunted hypertrophy in controls, reduc-
ing wall thickness and chamber size and improving FS, but had 
no effect on these properties in Rgs2–/– TAC hearts (Figure 5, A–C). 
Figure 3
Robust early myocardial activation of Gq-related cascades after TAC in Rgs2–/– mice. (A) Immunoblot blot for Cn protein expression in 1 wk TAC and 
summary data normalized to GAPDH. (B) RCAN-1 mRNA expression (Cn activity) in hearts of mice subjected to 48 h and 1 wk TAC (n = 4–6 per 
group). (C) Phosphorylated (p; Thr286) and total (t) expression of CaMKII in hearts of mice subjected to 48 h and 1 wk TAC. Summary graph shows 
phosphorylated/total (p/t) CaMKII ratio. (D) Phosphorylated and total protein expression for MAPKs ERK1/2, JNK, and p38 assessed at baseline 
and after 48 h and 1 wk TAC. Summary bar graphs (n = 3–6 for each) show phosphorylated/total expression ratios for each kinase. *P < 0.05 versus 
respective sham; †P < 0.05 versus respective Rgs2+/+ control; §P < 0.05 versus Rgs2–/– sham; #P < 0.05 versus respective 1 wk TAC.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 2   February 2009 413
Sildenafil also improved contractility and relaxation in Rgs2+/+ 
mice exposed to TAC, which was not observed in Rgs2–/– mice (Fig-
ure 5, D and F). As previously reported (21), sildenafil did not itself 
reduce cardiac afterload (Figure 5E).
Because Rgs2–/– mice displayed greater activation of Gq-linked 
pathways (Cn, CaMKII, and ERK1/2), we tested whether silde-
nafil suppresses these signaling pathways in Rgs2+/+ and Rgs2–/– 
hearts. Activation of each enzyme was indeed blunted by silde-
nafil cotreatment in Rgs2+/+ TAC hearts, an effect not observed 
in Rgs2–/– TAC hearts (Figure 6, A–C).
Regulation of RGS2 by PKG-1α. Because PKG interacts with pro-
teins other than RGS2, the absence of PDE5 inhibition effects in 
Rgs2–/– mice raised the question of whether PKG activation had in 
fact occurred in these hearts. Baseline PKG activity was not signifi-
cantly different between models (P = 0.2), and importantly, both 
displayed similar relative increases in activity after 1 wk TAC and 
Figure 4
Gαq as a critical target of RGS2. (A) Inhibition of PLCβ with U73122 prevents exacerbated hypertrophy (heart weight/tibia length), chamber 
dilation, and dysfunction (n = 7–14 per group). *P < 0.001 versus other groups. (B) In Rgs2–/– mice subjected to 48 h TAC, the inactive control 
agent U73343 did not suppress pathological remodeling. Summary echo data are provided in Supplemental Figure 2B. (C) Cardiac hypertrophy 
was exacerbated in double-mutant Gαq-OE+Rgs2–/– mice (n = 7–9 per group). **P < 0.01 versus other groups. (D) Corresponding echocardio-
grams showed worsened function and chamber dilation. (E) Summary data for LV diastolic dimension, FS, and heart rate (n = 7–9 per group). 
*P < 0.05 versus other groups; †P < 0.05 versus all Gαq-OE– groups. (F) Response of cardiac LV mass and echocardiographic FS in mice sub-
jected to swimming versus sedentary animals. Exercise-induced hypertrophy was similar in Rgs2+/+ and Rgs2–/– mice, with no change in FS. 
*P < 0.01, †P < 0.05 versus respective week-0 baseline.
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substantial further enhancement with sildenafil treatment (Figure 
7A; P = 0.37, genotype and genotype × condition; P < 0.0001, con-
dition effect; 2-way ANOVA). Thus, the lack of a sildenafil effect in 
Rgs2–/– could not be attributed to lack of PKG activation per se.
PKG-1α activates RGS2 in vascular smooth muscle (19), leading 
to translocation of both proteins to the outer cell membrane; fur-
thermore, PKG-1α is the prominent isoform in the heart (25). There-
fore, we examined the localization of both proteins in cardiac myo-
cytes. In control cells, RGS2 displayed faint diffuse cytosolic and 
membrane localization, whereas PKG-1α was diffusely distributed 
with a somewhat striated pattern (Figure 7B). After 2 h exposure 
to the Gq agonist ET1, both RGS2 and PKG-1α intensified at the 
outer membrane (Figure 7B). Identical results were obtained using 
angiotensin II stimulation (data not shown). This translocation 
was fully blocked by coincubation with the specific PKG peptide 
inhibitor DT2 (26) and was conversely stimulated by 8Br-cGMP 
Figure 5
Amelioration of pressure load–induced cardiac hypertrophy/remodeling via PDE5 inhibition with sildenafil is absent in Rgs2–/– mice. (A) Sildenafil 
(Sil) suppressed hypertrophy in Rgs2+/+, but not Rgs2–/–, mice (n = 8–13 per group). (B and C) Representative echocardiograms and summary 
data showing response to 1 wk TAC (T) with or without sildenafil treatment (n = 7–9 per group). S, sham. (D) Effects of sildenafil on LV PV loops. 
(E) Sildenafil did not alter the increase in LV afterload in either genotype (n = 4–7 per group). (F) Summary invasive PV loop results (n = 4–7 
per group). Sildenafil improved systolic and diastolic function in Rgs2+/+ TAC hearts, but had no effect in Rgs2–/– TAC hearts. *P < 0.05 versus 
respective sham control; ‡P < 0.05 versus respective 1 wk TAC; †P < 0.05 versus Rgs2+/+ TAC; §P < 0.05 versus Rgs2–/– sham.
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(Figure 7B). Importantly, translocation of both proteins was also 
observed after TAC in Rgs2+/+ hearts, evident at 48 h and declining 
by 1 wk. Sildenafil treatment enhanced membrane localization 
of both proteins after 1 wk TAC, consistent with enhanced PKG 
activity. In Rgs2–/– cells, basal PKG-1α localization was similar to 
Rgs2+/+ cells (Supplemental Figure 4A). Intriguingly, PKG-1α also 
translocated to the outer membrane after 48 h TAC; however, this 
was mostly absent by 1 wk TAC (Figure 7C). Moreover, unlike con-
trols, concomitant inhibition of PDE5 did not significantly alter 
this localization. These confocal results were confirmed by cell-
fraction protein immunoblots (Figure 7D; gel loading data pro-
vided in Supplemental Figure 4B).
Discussion
The present study demonstrates a major cardiac regulatory role 
for RGS2 as a critical brake against the Gαq/PLCβ pathway in the 
early cardiac stress response to pressure overload. Without RGS2, 
pressure overload induced rapidly exacerbated hypertrophy and 
dysfunction, amplified Gq-coupled signaling, and early mortality. 
Deletion of Rgs2 in Gαq transgenic hearts worsened dilation and 
hypertrophy, whereas inhibiting PLCβ blocked the rapid deterio-
ration and hypertrophy after TAC in Rgs2–/– hearts. Swimming, a 
non–Gaq-coupled stress (1, 27), had no adverse effect in these mice. 
Finally, we showed that the capacity of cGMP/PKG stimulated by 
PDE5 inhibition to blunt hypertrophy and enhance cardiac func-
tion within the first week of pressure overload stress was critically 
coupled to RGS2 and its suppression of Gq signaling.
Rgs2–/– mice exhibited a very rapid hypertrophic response to pres-
sure overload, revealing both the early potency of Gq stimulation 
and a key role of its suppression by RGS2 to permit early compen-
sation. This finding demonstrates that the transition from adap-
tive to maladaptive hypertrophy involves not only the magnitude 
and duration of proremodeling stimuli, but also the robustness 
and sustainability of critical countermeasures that blunt their 
toxicity. Stimulation of Gq by TAC can reflect both receptor/ago-
nist interaction from neurohormones and mechanical stretch, 
as described previously via the angiotensin II receptor (28, 29). 
The Rgs2–/– phenotype is somewhat unusual in that animals have 
Figure 6
Sildenafil suppresses Gαq-coupled molecular cascades in Rgs2+/+, but not Rgs2–/–, hearts. (A) Protein expression for Cn. (B and C) 
Phosphorylated and total protein expression for CaMKII (B) and ERK1/2 (C). Summary data are shown for each (n = 3–6 per group). ‡P < 0.05 
versus Rgs2+/+ 1 wk TAC.
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Figure 7
Regulation of RGS2 by PKG-1α. (A) PKG is similarly activated with and without concomitant sildenafil treatment in both genotypes. *P < 0.05 
versus respective sham; #P < 0.005 versus TAC alone. (B) Subcellular localization of RGS2 and PKG-1α in Rgs2+/+ mouse adult cardiac myo-
cytes by immunohistochemistry using confocal microscope. Images represent baseline (control), ET1 stimulation, ET1 stimulation with PKG 
inhibitor (ET1+DT2), and PKG stimulation with 8Br-cGMP. More than 20 cells were analyzed from 1 experiment, and experiments were repeated 
3 times. Original magnification, ×200. (C) Translocation of PKG-1α to outer membrane with 48 h TAC occurred in both genotypes and declined 
somewhat after 1 wk in Rgs2+/+ mice but was virtually absent in Rgs2–/– mice at the same time. Sildenafil treatment restored membrane localiza-
tion and enhanced RGS2 membrane signal in Rgs2+/+ cells, but had no impact in Rgs2–/– cells. Original magnification, ×200. (D) Immunoblot of 
PKG-1α from cytosolic (soluble [S]) and membrane (particulate [P]) fractions in sham control, 48 h, and 1 wk TAC myocardium. Summary data 
of particulate/soluble ratio is shown at right (n = 3–6 per group). *P < 0.001 versus sham; †P < 0.001 versus 1 wk TAC; ‡P < 0.001 versus 48 h 
TAC. Equal protein loading was confirmed by Ponceau staining (Supplemental Figure 4B).
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normal heart function and LV mass at rest, yet develop marked 
hypertrophy, dilation, and early mortality after TAC. Genetic 
models lacking cardiac protective or structural genes that exhibit 
early mortality after TAC (e.g., gp130 and integrin β1–interacting 
protein; refs. 30, 31) dilate without hypertrophy, whereas others 
(e.g., dominant-negative thioredoxin-1 and inactivated glycogen 
synthase kinase–3β; refs. 32, 33) induce hypertrophy that worsens 
further with TAC, yet do not display early lethality.
Other RGS proteins, such as RGS3 and RGS4, may also be 
involved in hypertrophy and failure regulation (10, 34), although 
these proteins are less specific to Gq (6). Mice with myocyte-target-
ed RGS4 overexpression exhibit a complex phenotype, developing 
rapid dilation and early mortality (1–2 days) without hypertrophy 
after exposure to TAC, but survivors exhibit less eventual hypertro-
phy (11). When these animals are genetically crossed with Gαq-OE+ 
mice, cardiac abnormalities in the latter strain are ameliorated (9). 
Thus, RGS4 may have protective roles in the later stages of disease, 
consistent with its upregulation in end-stage human heart failure 
(7, 35). RGS4 may also mediate ameliorative effects of natriuretic 
peptides on cardiac stress remodeling, although in vivo support 
for this hypothesis is so far based on the ability of RGS4 overex-
pression to blunt the cardiac phenotype in mice genetically lacking 
natriuretic peptide receptor–coupled guanylate cyclase–A (10).
RGS2 modulates stress response signaling by several mecha-
nisms (36, 37). First, it inactivates the Gαq subunit, which can 
suppress downstream Ca2+-activated cascades (including Cn and 
CaMKII) and MAPKs (including ERK and JNK), as shown in the 
current study. Cn and CaMKII in particular are considered potent 
contributors to maladaptive remodeling (22, 38). The results of 
the present studies using PLCβ inhibition, genetic deletion of Rgs2 
in Gαq-OE+ mice, and swimming exercise support RGS2 suppres-
sion of Gαq/PLCβ signaling as a central feature of its cardioprotec-
tive effects. RGS proteins can also inhibit Gβγ-induced signaling 
by reforming the G protein heterotrimer, and this could influence 
Akt/glycogen synthase kinase–3β cascades (39), which we have 
previously shown to be suppressed by PDE5 inhibition (21). RGS 
proteins can further bind to effecter enzymes, such as adenylate 
cyclase and PKC isoforms, to blunt signaling (40), although the 
role of this modulation in heart remains unknown.
While RGS2 has high affinity for Gq, it can suppress Gi/o or Gs in 
some cell types. For example, it regulates presynaptic Ca2+ channels 
via Gβγ subunits in neurons (41) and impacts carbachol-stimulated 
activation of ERK and Akt in COS cells via Gi/o interaction (42). RGS2 
blunts Gs-coupled cAMP accumulation triggered by parathyroid hor-
mone–related peptide (43). However, the effects of RGS2 over Gi/o or 
Gs appear to be unimportant in adult cardiac myocytes, as neither 
muscarinergic nor β-adrenergic cAMP regulation is altered by RGS2 
overexpression in contrast to RGS3, RGS4, or RGS5 (6).
Even though PDE5 is more abundantly expressed in vascu-
lar smooth muscle, antihypertrophic effects from its inhibition 
are likely caused by direct cardiac effects. First, as demonstrated 
in the present study, cardiac afterload associated with TAC was 
unchanged by sildenafil treatment. Second, PDE5 inhibition sup-
presses Cn/nuclear factor of activated T cell (Cn/NFAT) signaling 
and expression of the genes encoding atrial and brain natriuretic 
peptides in isolated myocytes stimulated with a Gq agonist (21, 
44). Third, knockdown of the gene encoding PDE5 in cardiac 
myocytes is antihypertrophic, having an impact similar to that of 
sildenafil, and the effect of combining both is similar to that of 
each alone (44). This last finding supports specificity of sildena-
fil for inhibiting PDE5. The improvement in cardiac function by 
sildenafil involves several mechanisms, including enhanced myo-
cyte calcium cycling and a decline in PKCα activation (45), both 
potentially linked to RGS2 suppression of Gαq/PLCβ.
Growing evidence supports an important role for myocardial 
cGMP/PKG signaling as an intrinsic brake to suppress maladap-
tive cardiac stress remodeling (46); however, only recently have 
studies revealed potential mechanisms for this effect. The first 
reported target was Cn/NFAT, which can be suppressed in neona-
tal myocytes by enhancing cGMP (e.g., NO donors) or expressing 
activated PKG (47). PDE5 inhibition was shown to have a similar 
effect in vivo (21), and our present data further support this. PKG 
also blunts RhoA activation by phosphorylation at Ser188 (48), 
although whether this applies to myocytes remains unknown. PKG 
phosphorylates SMAD3 at Ser309 and Thr388 in fibroblasts, pre-
venting its nuclear translocation to block TGF-β1 activation (49). 
This may be important for how PDE5 inhibitors suppress fibro-
sis. PKG can also block p38 autophosphorylation coupled to its 
binding to the scaffold protein TGF-β–activated protein kinase 1– 
binding protein 1 (TAB1) in ischemia/reperfusion injury (50), 
although this mechanism does not appear to be involved in 1 wk 
TAC. While the latter pathways involve direct PKG phosphoryla-
tion, similar mechanisms have not been identified for Cn/NFAT 
or CaMKII suppression. However, as these enzymes are coupled to 
Gq stimulation, suppression of the proximal signal by RGS2-PKG 
activation could provide a mechanism as well as explain reduced 
RhoA and TGF-β stimulation.
In vascular smooth muscle cells, activation of RGS2 by the nitric 
oxide/cGMP pathway requires binding to PKG-1α and its phos-
phorylation at Ser46 and Ser64 by PKG-1α, but RGS2 does not 
need the Gq-coupled pathway to be activated (19). cGMP stimu-
lation also increases the association of the smooth muscle cell 
plasma membrane with wild-type but not mutant (S46,64A) RGS2 
(51), highlighting the importance of PKG activity for this associa-
tion and GPCR modulation. The current study is the first to our 
knowledge to show that PKG-1α rapidly translocates to the outer 
plasma membrane from a resting cytosolic distribution in adult 
mouse myocytes in vitro and in vivo, concurrent with RGS2 plas-
ma membrane localization, and that PKG activation is required 
for this movement. The acute movement of PKG-1α to the plasma 
membrane even in Rgs2–/– cells indicates that another chaperone is 
involved, if not more than one. This may require binding to the leu-
cine zipper motif in PKG-1α, as deletion of this motif in PKG-1β — 
the other isoform harboring the only difference at leucine zipper 
motif — translocates the enzyme to the nucleus upon activation in 
BHK cells (52). Importantly, PKG-1α translocation was more tran-
sient in Rgs2–/– myocytes than in controls and did not provide anti-
hypertrophic protection. Rgs2–/– TAC hearts showed relative PKG 
activation by 1 wk sildenafil treatment similar to that of Rgs2+/+ 
hearts; thus, compartmentalization of this signal and its specific 
interaction with RGS2 appears to be central to its capacity to sup-
press Gq signaling and maladaptive hypertrophy.
Our study has several limitations. The Rgs2–/– mice globally 
lacked the gene, and though cardiac function was unchanged 
(observed even in 10-month-old animals; Supplemental Table 3), 
adaptive responses to sustained modest hypertension could still 
occur. Although there were no basal differences in the signaling 
cascades examined, our analysis was admittedly quite focused. 
Importantly, TAC-induced pressure overload was similar in both 
genotypes, and whatever adaptations may have existed, they failed 
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to compensate to the higher afterload. The blood pressure dispar-
ity we observed was somewhat less than originally reported (17), 
yet similar to other studies using the same mouse model (53). 
Some of this disparity may relate to the anesthesia used in our 
protocol. Because the gene was absent from conception, we cannot 
yet assess the role of RGS2 in the later stages of pressure overload 
disease. Such assessment will require an inducible gene deletion 
model currently under development. However, our present results 
indicate that a dominating PKG effecter in the initial response to 
pressure overload is RGS2.
In summary, our study demonstrates an essential role for RGS2 
— inhibiting the Gαq/PLCβ pathway — in early compensatory 
hypertrophy development to pressure overload and provides a 
mechanism for antihypertrophic effects associated with PKG 
enhancement from PDE5 inhibition. This coactivation provides 
what we believe to be the most proximal target for PKG-mediated 
inactivation of hypertrophy stimulation thus far described and 
can explain how multiple distal pathways can be concomitantly 
suppressed by PDE5 inhibition.
Methods
Animal models. Rgs2–/– mice, which harbor a global RGS2 deletion, and 
Rgs2+/+ littermate controls in C57BL/6 background were as reported pre-
viously (19), originally developed by J. Penninger (54). Gαq-OE+ mice (40 
copies of the transgene, FVB background; ref. 24), generously provided 
by G. Dorn (Washington University Center for Pharmacogenomics, 
St. Louis, Missouri, USA), were crossed with Rgs2–/– animals to gener-
ate animals lacking Rgs2 and overexpressing Gαq in the heart. The same 
generation of animals (Gαq-OE–Rgs2+/+, Gαq-OE+Rgs2+/+, Gαq-OE–Rgs2–/–, 
Gαq-OE+Rgs2+/+) was also studied.
TAC. Pressure overload was produced by TAC in male Rgs2–/– and Rgs2+/+ 
animals of 4–5 months of age (mean BW, 26 g) as previously described 
(21). Briefly, animals were anesthetized with isoflurane (2%–3%), intubated, 
and mechanically ventilated. The transverse aorta was constricted with a 
26-gauge needle using 7-0 prolene suture, after which the chest was closed 
and the animal was allowed to recover from anesthesia. Control mice were 
subjected to sham operations, and animals were studied 48 h to 1 wk after 
surgery. Sets of male Rgs2–/– animals were subjected to 48 h TAC and treat-
ed daily with 2.5 mg/kg/d U73122, a specific PLCβ inhibitor, or U73343, 
its inactive analog, in peanut oil via i.p. injection. Additional animals in 
either genotype were subjected to 1 wk TAC while cotreated with sildenafil 
(200 mg/kg/d) mixed in food (Bioserve soft diet).
Swimming exercise. Male Rgs2–/– and Rgs2+/+ animals (3 months of age; 
23–25 g BW) were studied. The forced swimming program was a modified 
6-wk protocol based on a prior method (55). Control animals remained 
sedentary in a cage for 6 wk. Briefly, 10 mice at a time swam twice daily in a 
45-cm by 75-cm container with the water kept at approximately 32°C. Ses-
sions began at 10 min and were increased by 10-min increments each day 
until each session lasted 90 min; this was then maintained for the remain-
der of the 6-wk period. Constant monitoring ensured the safety of the mice 
and prevented them from floating or holding their breath under water. All 
animal protocols were approved by the Animal Care and Use Committee 
of Johns Hopkins University.
Echocardiography. In vivo cardiac morphology was assessed by transthorac-
ic echocardiography (Acuson Sequoia C256, 13-MHz transducer; Siemens) 
in conscious mice (21). M-mode LV end-systolic and end-diastolic dimen-
sions were averaged from 3–5 beats. LV percent FS and LV mass were cal-
culated as described previously (21). Wall thickness of lateral free wall and 
intraventricular septum were averaged. Studies and analysis were performed 
by investigators blinded to genotype or heart condition.
In vivo hemodynamics. In vivo LV function was assessed by PV catheter 
as described previously (21). Briefly, mice were anesthetized with 1%–2% 
isoflurane, 750–100 mg/kg urethane i.p., 5–10 mg/kg etomidate i.p., and 
1–2 mg/kg morphine i.p.; were subjected to tracheostomy; and were venti-
lated with 6–7 μl/g tidal volume and 130 breaths/min. Volume expansion 
(12.5% human albumin, 50–100 μl over 5 min) was provided through a 
30-gauge cannula via the right external jugular vein. The LV apex was 
exposed through an incision between the seventh and eighth ribs, and 
a 1.4-Fr PV catheter (SPR 839; Millar Instruments Inc.) was advanced 
through the apex to lie along the longitudinal axis. Absolute volume was 
calibrated, and PV data were measured at steady state and during transient 
reduction of venous return by occluding the inferior vena cava with a 6-0 
silk snare suture. Data were digitized at 2 kHz, stored to disk, and analyzed 
with custom software. From the 10–15 successive cardiac cycles during the 
inferior vena cava occlusion, the end-systolic PV relation slope (i.e., end-sys-
tolic elastance) and stroke work–end-diastolic volume relation (i.e., preload 
recruitable stroke work) were derived.
Tissue histology. Myocardium fixed with 10% formalin was analyzed for myo-
cyte hypertrophy and fibrosis. Tissue was paraffin embedded, cross-sectioned 
into 5- to 8-μm slices, and stained with H&E or Masson’s trichrome staining 
(21). We analyzed 6 serial sections of mid-LV per heart. To assess mean car-
diomyocyte diameter and interstitial collagen fraction, 6–8 regions of photo-
micrographs covering the whole section were obtained and quantified using 
computer-assisted image analysis (Adobe Photoshop version 5.0 and NIH 
Image J). Average data reflect results from 4–5 hearts per group (>50 cells).
Western blot analysis. Protein was prepared from snap-frozen heart tissue 
or isolated cardiac myocytes, and fractionation was performed as previous-
ly described (21, 56). After homogenization in 25 mM Tris-HCL, pH 7.5, 
4 mM EGTA, 2 mM EDTA, 5 mM dithiothreitol, 1 mM phenylmethylsulfo-
nyl fluoride, and 1 μM leupeptin and incubation on ice for 30 min, samples 
were spun at 100,000 g for 30 min at 4°C. The supernatant was saved as the 
cytosolic fraction, and the pellet was resuspended in homogenization buf-
fer with 1% Triton X-100 added. This was processed as described previously 
(56), and the remaining supernatant was saved as the particulate fraction. 
Protein concentration was measured by BCA assay (Pierce Biotechnology). 
Protein extracts were run on 4%–12% Bis-Tris NuPage gels (Invitrogen), 
blotted onto nitrocellulose membranes, and probed with the following pri-
mary antibodies: rabbit polyclonal antibody generated against synthesized 
peptide KKPQITTEPHAT corresponding to RGS2 C terminus; Cn (diluted 
1:500; BD Biosciences; ref. 21); Thr286–phospho-CaMKII (diluted 1:1,000; 
Affinity BioReagents); ERK, Thr202/Thr204–phospho-ERK, JNK, Thr183/
Tyr185–phospho-JNK, p38, and Thr180/Tyr182-p38 (diluted 1:1,000; Cell 
Signaling Technology; ref. 21); PKG-1α (diluted 1:1,000); and GAPDH 
(diluted 1:3,000; IMGENEX or Cell Signaling Technology). Antibody bind-
ing was visualized by horseradish peroxidase–conjugated secondary anti-
bodies and enhanced chemiluminescence (Pierce Biotechnology).
Quantitative real-time PCR. Total RNA was extracted from snap-frozen 
heart tissue using TRIzol reagent (Invitrogen; ref. 21). The yield and puri-
ty of RNA was estimated spectrophotometrically using A260/A280 ratio. 
RNA (1 μg) was reverse transcribed into cDNA using SuperScript first-
strand synthesis system (Invitrogen). cDNA was subjected to PCR ampli-
fication using TaqMan PCR Master Mix reagent (Applied Biosystems). 
TaqMan primers and probes for Rgs2, Nppa, Nppb, Myh7, Atp2a2, Rcan1, 18S, 
and Gapdh were purchased from Applied Biosystems.
Adult mouse myocyte preparation and immunohistochemistry. Mouse adult 
ventricular myocytes were isolated, fixed, and stained for confocal 
immunohistochemistry as described previously (57). Cells were plated 
on laminin-coated 6-well dishes in medium, and incubated in Tyrode’s 
solution with angiotensin (1 μM for 2 h; Sigma-Aldrich) or ET1 (0.5 μM 
for 2 h; Sigma-Aldrich) in the presence or absence of DT2 compound 
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(5 μM; Biolog; ref. 26) or 8Br-cGMP (1 mM for 1 h; Sigma-Aldrich; ref. 
19). Cells were fixed with 50% methanol and 50% acetone, permeabilized 
with 0.1% saponin in PBS, blocked in 10% BSA in PBS, incubated over-
night with primary antibodies at 4°C (goat anti-RGS2, diluted 1:100; 
Santa Cruz Biotechnology Inc.; rabbit anti–PKG-1α, diluted 1:400), and 
subsequently incubated with secondary antibodies for 1 h at room tem-
perature (Alexa Fluor 546–conjugated donkey anti-goat and Alexa Fluor 
488–conjugated donkey anti-rabbit; Invitrogen). Imaging was performed 
on a Zeiss inverted epifluorescent microscope (Carl Zeiss Inc.) attached 
to an argon-krypton laser confocal scanning microscope (UltraView; 
Perkin Elmer Life Science Inc.).
Protein synthesis of adult mouse cardiac myocytes. Protein synthesis was 
measured by [3H] leucine incorporation. After overnight culture, cells 
were stimulated with 100 nM ET1. After ET1 stimulation, [3H] leucine 
(1 μCi/ml) was add to the culture medium, and cells were further incu-
bated for 24 h. The incorporated [3H] leucine was measured using a 
liquid-scintillation counter.
Statistics. All values are expressed as mean ± SEM. Group data were com-
pared using 1- or 2-way ANOVA (with genotype and sham or TAC as cate-
gories) and Tukey’s post-hoc multiple-comparisons test for between-group 
differences. Comparisons between 2 groups were made using nonpaired 
2-tailed Student’s t test. A P value less than 0.05 was considered significant. 
Sample sizes and individual statistical results for all analyses are provided 
in the figures, supplemental figures, and supplemental tables.
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